FGFR2 and neoplasm: Tumor microenvironment adaptations also present a challenge to target FGFR2, as diffuse-type gastric cancer cells can switch their driver pathways from FGFR2b expression to CXCR4 under hypoxia via SDF1 produced by cancer associated fibroblasts [85].